Compare CAVA & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAVA | RDY |
|---|---|---|
| Founded | 2006 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 9.9B |
| IPO Year | 2023 | 2001 |
| Metric | CAVA | RDY |
|---|---|---|
| Price | $51.87 | $12.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 1 |
| Target Price | ★ $91.00 | $16.90 |
| AVG Volume (30 Days) | ★ 3.2M | 2.3M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $1,179,664,000.00 | N/A |
| Revenue This Year | $25.71 | $7.72 |
| Revenue Next Year | $20.57 | $3.50 |
| P/E Ratio | $137.21 | ★ $18.67 |
| Revenue Growth | ★ 22.41 | N/A |
| 52 Week Low | $43.41 | $11.36 |
| 52 Week High | $98.79 | $15.67 |
| Indicator | CAVA | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 33.86 | 53.46 |
| Support Level | $49.68 | $12.09 |
| Resistance Level | $74.08 | $12.48 |
| Average True Range (ATR) | 2.21 | 0.20 |
| MACD | 0.09 | 0.07 |
| Stochastic Oscillator | 19.49 | 64.05 |
Cava Group Inc owns and operates a chain of restaurants. It operates a Mediterranean-inspired fast-casual restaurant brand offering menu items. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: i) CAVA: It includes the operations of all company-owned CAVA restaurants, and ii) CAVA Foods: It includes the production of dips, spreads, and certain dressing bases used in CAVA restaurants as well as sales from the Company's consumer packaged goods business. The company generates the majority of its revenue from the CAVA segment.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.